ASTERDM · NSE
Aster DM Quality Care Limited
₹779.3
+5.41% (+₹40)
Prev. close
₹739.3
Volume
26,65,994
Delivery %
51.0%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
2 analyst stances · last 90 days · one per analyst
Trackable
2 · 2 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Aster DM Quality Care Ltd, with a target price of ₹835, implying a 23% upside from a CMP of ₹681. The brokera…” | Monarch Networth Capital AnalysisMonarch Networth Capital | Aster DM Healthcare Ltd | PENDING | |
| “Bullish on Aster DM Quality Care with a target price of ₹920, indicating an upside of 35% from its current market price …” | PL Capital AnalysisPL Capital | Aster DM Quality Care Ltd | PENDING | |
| “Recommends buying Aster DM Quality Care for intraday trading at ₹869.50, targeting ₹910, with a stop loss at ₹852.” | Vaishali ParekhPrabhudas Lilladher | Aster DM Healthcare | MISS | |
| “Bullish on Aster DM Healthcare, recommending a buy at 808 with a target of 868 and a stop loss at 769. The stock is trad…” | Rupak DeLKP Securities | Aster DM Healthcare | HIT | |
| “Recommends buying Aster DM Healthcare at ₹700.75 with a target of ₹735 and a stop loss at ₹683.” | Vaishali ParekhPrabhudas Lilladher | Aster DM Healthcare | MISS | |
| “Bullish on Aster DM Healthcare Limited, recommending a buy between ₹625-640 with a target of ₹720 in two to three months…” | Marketsmith India AnalysisMarketsmith India | Aster DM Healthcare Limited | HIT | |
| “Bullish on Aster DM Healthcare Ltd, recommending a buy between ₹625–640 with a target price of ₹720 in two to three mont…” | Marketsmith India AnalysisMarketsmith India | Aster DM Healthcare Ltd | HIT | |
| “Recommends buying Aster DM Healthcare (ASTERDM) above ₹601 and on dips to ₹585, with a stop loss at ₹578 and targets bet…” | Raja VenkatramanNeoTrader | Aster DM Healthcare | HIT | |
| “Recommends buying Aster DM Healthcare with a target price of ₹700. The call implies a bullish outlook on the stock.” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aster DM Healthcare | HIT | |
| “Bullish on Aster DM Healthcare, recommending buying, holding, and accumulating the stock. It has registered an all-time …” | Rajesh PalviyaAxis Securities | Aster DM Healthcare | MISS | |
| “Bullish on Aster DM, recommending a buy above ₹477 with a stop loss at ₹465. He targets ₹520-540 in three months, noting…” | Raja VenkatramanNeoTrader | Aster DM Healthcare Ltd | HIT | |
| “Bullish on Aster DM Healthcare, recommending to buy above ₹477 with a stop loss at ₹465 and a target of ₹520-540. This r…” | Raja VenkatramanNeoTrader | Aster DM Healthcare | HIT | |
| “JM Financial has upgraded Aster DM Healthcare to a BUY rating with a revised target price of Rs 532, implying a 34% upsi…” | JM Financial AnalysisJM Financial Institutional Securities | Aster DM Healthcare Ltd | PENDING | |
| “Aster DM Healthcare is in a sideways to slightly positive trend. It faces resistance at 420; if crossed, it could rise t…” | Riyank AroraMehta Equities | Aster DM Healthcare Ltd | HIT | |
| “Upgraded Aster DM Healthcare to BUY with a target price of ₹532, suggesting a 34% upside. The merger with QCIL positions…” | JM Financial AnalysisJM Financial Institutional Securities | Aster DM Healthcare Ltd | PENDING | |
| “Prabhudas Lilladher recommends buying Aster DM Healthcare with a target price of ₹620. The call implies a bullish outloo…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aster DM Healthcare | HIT | |
| “Bullish on Aster DM Healthcare with a target price of ₹735 for CY25. Aster DM Healthcare is included in their list of to…” | BNP Paribas Research AnalysisBNP Paribas Research | Aster DM Healthcare | MISS | |
| “Recommends buying Aster DM Healthcare in the range of ₹485-455, targeting ₹613 and potentially ₹685, expecting a decent …” | Axis Securities AnalysisAxis Securities | Aster DM Healthcare | HIT | |
| “Recommends buying Aster DM Healthcare at ₹448.75 with a target of ₹470 and a stop loss at ₹432 for intraday trading on M…” | Sumeet BagadiaChoice Equity Broking | Aster DM Healthcare | PENDING | |
| “Bullish on Aster DM Healthcare Ltd, which has shown a short-term trend reversal with higher tops and bottoms and a break…” | Rajesh PalviyaAxis Securities | Aster DM Healthcare Ltd | PENDING |
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Aster DM Healthcare, recommending a buy in the range of ₹470–487 with a profit goal of ₹560 and a stop loss a…” | Marketsmith India AnalysisMarketsmith India | Aster DM Healthcare | — | |
| “Recommends buying Aster DM Healthcare in the range of ₹470–487, targeting a profit goal of ₹560 with a stop loss at ₹448…” | Marketsmith India AnalysisMarketsmith India | Aster DM Healthcare | — | |
| “Aster DM Healthcare has surged over 4% and is approaching key resistance at 420 (200 and 20 Daily Simple Moving Average)…” | Rajesh BhosaleAngel One | Aster DM Healthcare Ltd | — |
Fundamentals
About Aster DM Quality Care Limited
Aster DM Quality Care Limited operates as an integrated healthcare provider in India. The company operates through Hospitals & Clinics, Labs, Wholesale Pharmacies, and Others segments. It offers comprehensive healthcare services including primary, secondary, tertiary and quaternary care in various specialty areas, including multi-specialty, cardiac sciences, OP pharmacy, anaesthesiology and others, neuro sciences, oncology, gastroenterology and integrated liver care, nephrology and urology, orthopaedics, women's health, and child adolescent health areas. The company also operates hospitals and clinics; wholesale pharmacies and optical outlets; and diagnostic labs. In addition, it provides healthcare consultancy and others services; and digital health platforms. The company offers its services and products under Aster DM, CARE Hospitals, Evercare, and KIMSHEALTH brands. Aster DM Quality Care Limited was formerly known as Aster DM Healthcare Limited and changed its name to Aster DM Quality Care Limited in July 2026. The company was founded in 1987 and is based in Bengaluru, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Varun Khanna
Headquarters
Bengaluru
Employees
15,773
Website
asterqualitycare.comExchange
View on NSE ↗Key stats
Market cap
₹62,649.32 Cr
P/E ratio (TTM)
116.6
Dividend yield
0.44%
EPS (TTM)
₹6.17
Beta (1Y · daily vs NIFTY 50)
0.41
Beta (5Y · monthly vs NIFTY 50)
0.85
Shares float
34.62 Cr
EPS · quarter ended Jun 2026
₹0.31
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss — as filed
Annual
| Line item | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|
| ₹8,456.87 Cr | ₹9,667.63 Cr | ₹3,451.22 Cr | ₹3,746.58 Cr | |
Profit before share of profit of equity accounted investees and tax | ₹201.53 Cr | ₹636.31 Cr | ₹272.53 Cr | ₹540.11 Cr |
Share of loss of equity accounted investees | ₹3.52 Cr | ₹54.00 L | ₹-11.34 Cr | ₹-18.91 Cr |
Exceptional Items | — | — | — | ₹-50.14 Cr |
Profit before tax | ₹205.05 Cr | ₹636.85 Cr | ₹261.19 Cr | ₹471.06 Cr |
Current tax | ₹21.66 Cr | ₹45.54 Cr | ₹32.40 Cr | ₹125.73 Cr |
Current tax for earlier years | — | ₹-1.73 Cr | — | — |
Deferred tax | ₹5.56 Cr | ₹-8.01 Cr | ₹24.11 Cr | ₹8.64 Cr |
Total Tax expense | ₹27.22 Cr | ₹35.80 Cr | ₹56.51 Cr | ₹134.37 Cr |
Profit for the year from continuing operations | — | — | ₹204.68 Cr | ₹336.69 Cr |
(a) Profit/ (loss) before Tax from discontinued operations | — | — | ₹69.11 Cr | ₹-76.89 Cr |
(b) Tax expense of discontinued operations | — | — | ₹62.23 Cr | — |
(c) Gain on disposal of business operations | — | — | — | ₹5,148.09 Cr |
Profit after tax from discontinued operations | — | — | ₹6.88 Cr | ₹5,071.20 Cr |
Profit for the year | ₹177.83 Cr | ₹601.05 Cr | ₹211.56 Cr | ₹5,407.89 Cr |
Remeasurement of net defined benefit liability | ₹-13.10 Cr | ₹43.88 Cr | ₹13.89 Cr | ₹-3.09 Cr |
Income tax on items that will not be reclassified subsequently to profit or loss | ₹4.00 L | ₹-90.00 L | ₹-1.48 Cr | ₹79.00 L |
Exchange difference in translating financial statements of foreign operations | ₹-36.65 Cr | ₹73.27 Cr | ₹44.22 Cr | ₹25.00 L |
Income tax on items that will be reclassified subsequently to profit or loss | — | ₹-22.80 Cr | ₹-10.21 Cr | ₹-6.00 L |
Other comprehensive income, net of taxes | — | ₹93.45 Cr | — | — |
Total other comprehensive income/ (loss), net of taxes | — | — | ₹46.42 Cr | ₹-2.11 Cr |
Total comprehensive income for the year | ₹128.12 Cr | ₹694.50 Cr | ₹257.98 Cr | ₹5,405.78 Cr |
| ₹177.83 Cr | ₹601.05 Cr | ₹211.56 Cr | ₹5,407.89 Cr | |
Owners of the Company | ₹147.74 Cr | ₹525.99 Cr | ₹129.28 Cr | ₹5,377.83 Cr |
Non-controlling interests | ₹30.09 Cr | ₹75.06 Cr | ₹82.28 Cr | ₹30.06 Cr |
Owners of the Company | ₹-43.79 Cr | ₹82.66 Cr | ₹42.61 Cr | ₹-2.04 Cr |
Non-controlling interests | ₹-5.92 Cr | ₹10.79 Cr | ₹3.81 Cr | ₹-7.00 L |
Other comprehensive income for the year | ₹-49.71 Cr | ₹93.45 Cr | — | — |
Other comprehensive income/ (loss) for the year | ₹-49.71 Cr | — | ₹46.42 Cr | ₹-2.11 Cr |
| ₹128.12 Cr | ₹694.50 Cr | ₹257.98 Cr | ₹5,405.78 Cr | |
Owners of the Company | ₹103.95 Cr | ₹608.65 Cr | ₹171.89 Cr | ₹5,375.79 Cr |
Non-controlling interests | ₹24.17 Cr | ₹85.85 Cr | ₹86.09 Cr | ₹29.99 Cr |
Basic | 2.97 | 10.58 | 3.60 | 6.16 |
Diluted | 2.97 | 10.57 | 3.60 | 6.15 |
Basic | — | — | ₹-1 | ₹101.82 |
Diluted | — | — | ₹-1 | ₹101.7 |
Basic | — | — | ₹2.6 | ₹107.98 |
Diluted | — | — | ₹2.6 | ₹107.85 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹8,014.45 Cr | ₹8,449.78 Cr | ₹9,959.64 Cr | ₹3,826.01 Cr | ₹4,704.91 Cr | |
Inventories | ₹848.99 Cr | ₹1,025.68 Cr | ₹1,305.62 Cr | ₹110.52 Cr | ₹92.35 Cr |
Investments | ₹24.13 Cr | ₹6.64 Cr | ₹11.25 Cr | ₹3.30 Cr | ₹1.42 Cr |
Trade receivables | ₹2,019.00 Cr | ₹2,020.52 Cr | ₹2,336.31 Cr | ₹233.35 Cr | ₹257.81 Cr |
Cash and cash equivalents | ₹258.09 Cr | ₹343.37 Cr | ₹378.53 Cr | ₹82.23 Cr | ₹164.59 Cr |
Other bank balances | ₹23.27 Cr | ₹36.24 Cr | — | — | — |
Bank balances other than cash and cash equivalents above | — | — | ₹50.03 Cr | ₹30.42 Cr | ₹1,215.41 Cr |
Other financial assets | ₹112.93 Cr | ₹168.15 Cr | ₹188.83 Cr | ₹39.91 Cr | ₹116.19 Cr |
Other current assets | ₹342.60 Cr | ₹495.86 Cr | ₹650.99 Cr | ₹65.28 Cr | ₹53.70 Cr |
Assets classified as held for sale | — | — | — | — | ₹13,600.29 Cr |
Total current assets | ₹3,629.01 Cr | ₹4,096.46 Cr | ₹4,921.56 Cr | ₹14,165.30 Cr | ₹1,901.47 Cr |
Total assets | ₹11,643.46 Cr | ₹12,546.24 Cr | ₹14,881.20 Cr | ₹17,991.31 Cr | ₹6,606.38 Cr |
| ₹3,834.12 Cr | ₹4,482.62 Cr | ₹4,860.46 Cr | ₹5,030.11 Cr | ₹3,651.45 Cr | |
| — | — | ₹4,448.07 Cr | ₹4,559.79 Cr | ₹3,428.07 Cr | |
Non-controlling interests | ₹461.66 Cr | ₹529.21 Cr | ₹412.39 Cr | ₹470.32 Cr | ₹223.38 Cr |
Borrowings | ₹1,754.80 Cr | ₹1,466.40 Cr | ₹1,312.30 Cr | ₹446.08 Cr | ₹483.71 Cr |
Lease liabilities | ₹2,274.91 Cr | ₹2,472.92 Cr | ₹3,154.41 Cr | ₹690.40 Cr | ₹1,345.59 Cr |
Other financial liabilities | ₹42.55 Cr | ₹11.66 Cr | ₹216.49 Cr | ₹206.62 Cr | ₹5.95 Cr |
Provisions | ₹358.63 Cr | ₹358.94 Cr | ₹407.12 Cr | ₹33.11 Cr | ₹41.78 Cr |
Deferred tax liabilities | ₹152.59 Cr | ₹168.93 Cr | ₹238.06 Cr | ₹247.63 Cr | ₹146.12 Cr |
Other non-current liabilities | ₹30.24 Cr | ₹26.19 Cr | ₹37.08 Cr | ₹49.10 Cr | ₹52.57 Cr |
Total non-current liabilities | ₹4,613.72 Cr | ₹4,505.04 Cr | ₹5,365.46 Cr | ₹1,672.94 Cr | ₹2,075.72 Cr |
Borrowings | ₹554.27 Cr | ₹725.76 Cr | ₹975.18 Cr | ₹223.24 Cr | ₹158.47 Cr |
Lease liabilities | ₹219.67 Cr | ₹242.05 Cr | ₹258.41 Cr | ₹24.03 Cr | ₹30.00 Cr |
Total outstanding dues of micro and small enterprises | ₹5.20 Cr | ₹14.43 Cr | ₹15.58 Cr | ₹16.37 Cr | ₹19.46 Cr |
Total outstanding dues of creditors other than micro and small enterprises | ₹2,022.14 Cr | ₹2,103.66 Cr | ₹2,972.19 Cr | ₹442.33 Cr | ₹406.74 Cr |
| ₹3,195.62 Cr | ₹3,558.58 Cr | ₹4,655.28 Cr | ₹11,288.26 Cr | ₹879.21 Cr | |
Total equity and liabilities | ₹11,643.46 Cr | ₹12,546.24 Cr | ₹14,881.20 Cr | ₹17,991.31 Cr | ₹6,606.38 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹1,569.12 Cr | ₹1,314.04 Cr | ₹1,833.98 Cr | ₹157.81 Cr | ₹425.05 Cr | |
| — | — | — | ₹-884.65 Cr | ₹6,014.87 Cr | |
| ₹-330.30 Cr | ₹-570.48 Cr | ₹-971.88 Cr | — | — | |
Net cash generated from /(used in) financing activities (C) | ₹-1,116.13 Cr | ₹-686.00 Cr | ₹-817.39 Cr | ₹1,052.83 Cr | ₹-6,357.81 Cr |
Net increase in cash and cash equivalents (A+B+C) | ₹122.69 Cr | ₹57.56 Cr | ₹44.71 Cr | ₹325.99 Cr | ₹82.11 Cr |
Cash and cash equivalents at the beginning of the year | ₹114.65 Cr | ₹234.55 Cr | ₹299.33 Cr | ₹365.07 Cr | ₹82.23 Cr |
Effect of exchange rate changes on cash and cash equivalents | ₹-2.79 Cr | ₹7.22 Cr | ₹21.03 Cr | ₹6.40 Cr | ₹25.00 L |
Cash and cash equivalents at the end of the year* | ₹234.55 Cr | ₹299.33 Cr | ₹365.07 Cr | ₹697.46 Cr | ₹164.59 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21 | Dec 21 | Mar 22 | Jun 22–Sep 22(2Q) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Apr 25 | Jun 25 | Sep 25–Mar 26(3Q) | Jun 26 | Jul 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 37.88% | 37.88% | 37.88% | 37.88% | 37.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.88% | 41.89% | 40.38% | 40.39% | 40.39% | 40.39% | 53.72% |
| Public | 61.64% | 61.65% | 61.66% | 61.67% | 61.67% | 57.69% | 57.70% | 57.70% | 57.75% | 57.77% | 57.80% | 57.82% | 57.84% | 57.85% | 59.37% | 59.36% | 59.38% | 59.61% | 46.28% |
| Employee trusts | 0.48% | 0.47% | 0.46% | 0.45% | 0.44% | 0.43% | 0.42% | 0.41% | 0.37% | 0.35% | 0.32% | 0.30% | 0.28% | 0.26% | 0.25% | 0.25% | 0.23% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Aster DM Quality Care Limited | ₹59,323.34 Cr | ₹719.55 | 110.4 | 12.96 | 8.5% | 0.49 | +12.1% | +4.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.